The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerosis Development-Reference-Cited by-同舟云学术

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerosis Development

Published:2019-05-15 Issue:5 Volume:5 Page:112-120
ISSN:2414-2948
Container-title:Bulletin of Science and Practice
language:
Short-container-title:BSP

Author:

Chaulin A.¹^ORCID,Karslyan L.¹,Aleksandrov A.²,Mazaev A.¹,Grigorieva E.³,Nurbaltaeva D.³

Affiliation:

1. Samara State Medical University

2. INVITRO-Samara

3. Samara Regional Cardiology Dispensary

Abstract

Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new promising therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing low-density lipoprotein receptors (LDLR) degradation and preventing LDLR recirculation to the cell surface. In addition to examining the functional role of PCSK9, this review also discusses new drugs for the treatment of hyperlipidemia — PCSK9 inhibitors.

Publisher

Publishing Center Science and Practice

Subject

General Medicine

Reference30 articles.

1. Yan, A. T., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K. L., Kertland, H., & al. (2006). Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med, 119(8), 676-683. doi:10.1016/j.amjmed.2005.11.015

2. Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., … Nordestgaard, B. G. (2015). Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36(17), 1012–1022. doi:10.1093/eurheartj/ehv043

3. Al-Mohaissen, M. A., Ignaszewski, M. J., Frohlich, J., & Ignaszewski, A. P. (2016). Statin-associated muscle adverse events: update for clinicians. Sultan Qaboos Univ Med J., 16(4), e406-e415. doi:10.18295/squmj.2016.16.04.002

4. Page, M. M., & Watts, G. F. (2018). PCSK9 in context: a contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes Obes Metab, 20(2), 270-282. doi:10.1111/dom.13070

5. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., & al. (2003). The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA, 100(3), 928-933. doi:10.1073/pnas.0335507100

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammation in Atherosclerosis: From Theory to Practice;Bulletin of Science and Practice;2020-10-15